<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5062">
  <stage>Registered</stage>
  <submitdate>3/10/2014</submitdate>
  <approvaldate>3/10/2014</approvaldate>
  <nctid>NCT02273960</nctid>
  <trial_identification>
    <studytitle>Study to Evaluate Safety and Efficacy in Adult Subjects With ITP</studytitle>
    <scientifictitle>Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects With Primary Immune Thrombocytopenia (ITP)</scientifictitle>
    <utrn />
    <trialacronym>ITP</trialacronym>
    <secondaryid>2014-001429-33</secondaryid>
    <secondaryid>IM140-103</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Immune Thrombocytopenic Purpura</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-986004

Experimental: Arm A: BMS-986004 - BMS-986004 solution intravenously as specified

Experimental: Arm B: BMS-986004 - BMS-986004 solution intravenously as specified

Experimental: Arm C: BMS-986004 - BMS-986004 solution intravenously as specified

Experimental: Arm D: BMS-986004 - BMS-986004 solution intravenously as specified


Treatment: drugs: BMS-986004


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Short-Term Period: Safety measured by number of subjects with adverse events (AEs), serious adverse events (SAEs), ECG abnormalities</outcome>
      <timepoint>Day 1 to Day 141</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Short-Term Period: Safety measured by number of subjects with laboratory abnormalities including safety biomarkers of d-Dimer and Thrombin anti-Thrombin (TAT)</outcome>
      <timepoint>Day 1 to Day 141</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Long-Term Extension Period: Safety measured by number of subjects with AEs, SAEs, ECG abnormalities</outcome>
      <timepoint>Day 1 to Day 398</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Long-Term Extension Period: Safety measured by number of subjects with laboratory abnormalities including safety biomarkers of d-Dimer and TAT</outcome>
      <timepoint>Day 1 to Day 398</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Short-Term Period: Response rate (RR) of BMS-986004 - RR is defined as the proportion of subjects who are responders.</outcome>
      <timepoint>Day 1 to Day 141</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Long-Term Extension Period: Response rate (RR) of BMS-986004 - RR is defined as the proportion of subjects who are responders.</outcome>
      <timepoint>Day 1 to Day 398</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed serum concentration (Cmax) of BMS-986004</outcome>
      <timepoint>From Day 1 till Day 141</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986004</outcome>
      <timepoint>From Day 1 till Day 141</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough observed serum concentration (Ctrough) of BMS-986004</outcome>
      <timepoint>From Day 1 till Day 141</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total body clearance (CLT) of BMS-986004</outcome>
      <timepoint>From Day 1 till Day 141</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AUC accumulation index (AI_AUC); ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose of BMS-986004</outcome>
      <timepoint>From Day 1 till Day 141</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cmax accumulation index (AI_Cmax); ratio of Cmax at steady-state to Cmax after the first dose of BMS-986004</outcome>
      <timepoint>From Day 1 till Day 141</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        

          -  =18 years old, diagnosed with persistent or chronic ITP</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Secondary immune thrombocytopenia

          -  Drug induced thrombocytopenia</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>17/11/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>52</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>16/02/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD</recruitmentstate>
    <hospital>Local Institution - Randwick</hospital>
    <hospital>Local Institution - Brisbane</hospital>
    <postcode>2031 - Randwick</postcode>
    <postcode>4102 - Brisbane</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Georgia</country>
      <state>Tbilisi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Moldova, Republic of</country>
      <state>Chisinau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Chorzow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Smolensk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Lanarkshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the safety and tolerability of BMS-986004 when
      administered in subjects with ITP.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02273960</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>